LAUSANNE, Switzerland and CHIBA, Japan, April 21 /PRNewswire/ --
Debiopharm S.A., the independent drug-development company specialising in
oncology, endocrinology and niche products, announced today that it signed a
research collaboration with NanoCarrier Co., Ltd, a company specializing in
the development of drugs based on their proprietary micellar nanoparticle
drug delivery systems (DDS) technology, to develop a new platinum compound.
Under this collaboration, Debiopharm has the exclusive option to license-in a
DACH-platin-PEG-polyglutamic acid (DACH Platin Medicelle(TM)) from
NanoCarrier, for use in oncology. Preliminary animal experiments demonstrate
that the Medicelle(TM) technology offers enhanced permeability and retention
of the compound in the tumour, leading to improved efficacy and toxicity
Under the terms of the agreement, Debiopharm will fund the entire
development of the product. In addition, NanoCarrier will receive cash
milestones at different stages of the development and royalties when the
product is marketed.
The mechanism of action of Medicelle(TM) delivery system is based on the
formation of micelles, including hydrophilic-hydrophobic block co-polymers,
with a hydrophobic inner core and hydrophilic outer shell. This allows the
chemical entrapment of various drugs into the micelles. The drugs are then
released slowly into the organism.
"Coupling Debiopharm's expertise in oncology drug development,
particularly platinum compounds, with Nanocarriers's expertise in the
innovative Medicelle(TM) technology and manufacturing, gives us a high chance
of success to bring a better targeted, more efficacious, and safer drug to
cancer patients," said Rolland-Yves Mauvernay, President and CEO of
"It is a great pleasure to collaborate with Debiopharm, a company with
proven drug development expertise," commented Ichiro Nakatomi, NanoCarrier's
President and CEO. "Their cancer product Eloxatin(R) (oxaliplatin) is a
marketed blockbuster. This collaboration is also a great opportunity for
NanoCarrier's Medicelle(TM) Technology, which we hope will provide cancer
patients with a new class of targeted drugs."
Debio is an established group of four complementary companies,
Debiopharm, Debioinnovation, Debio R.P. and Debioclinic. Debiopharm, founded
in 1979 in Lausanne, Switzerland, focuses on evaluating compounds with
promising in-vivo results in animals to in-license, develop for global
registration, and out-license to sales and marketing pharmaceutical partners.
Debiopharm has proven expertise in drug development, having registered three
products: Eloxatin(R), one of sanofi-aventis' leading marketed products,
Decapeptyl(R), the leading product of Ipsen, and Trelstar(R) (1-and 3-month).
Together, their combined sales were in excess of $1.8 bn in 2004.
Debioinnovation was set up to complement the core business objectives of
Debiopharm through addressing the financing and partnering needs of
biotechnology, pharmaceutical start-up companies and life science incubators.
Debio R.P. is a leader in polymer-based controlled release technologies that
allow certain drugs like proteins, peptides and anti-cancers to be delivered
in customized, sustained-release formulation. From its FDA-inspected
manufacturing facility in Martigny, Switzerland, Debio R.P. also conducts
feasibility studies, formulation selection, optimization, scale-up and cGMP
manufacturing from clinical trial supplies to commercial scale. Debioclinic
is a contract research organization, specialized in oncology and dedicated to
clinical development, providing regulatory, biometric and clinical support in
line with cGCP.
For more information on Debiopharm, please visit our website at
NanoCarrier is a product focused, R&D-driven venture enterprise
headquartered in Chiba with a branch in Tokyo, Japan. NanoCarrier was
primarily established in 1996 to create nanometer-scale particles to deliver
a wide variety of pharmaceuticals from low molecular weight anti-cancer
agents to proteins, nucleic acids and diagnostic reagents, and to work in
partnership with leading researchers in the field. NanoCarrier possesses
various innovative technologies, including NanoCap(TM) for water insoluble
compounds, Medicelle(TM) for water-soluble drugs and other technologies
suitable for the delivery of proteins and nucleic acids. Using these delivery
technologies, NanoCarrier has acquired capabilities for the development of
drugs and is currently focusing on oncology. The DACH Platin formulation was
originally acquired by NanoCarrier from Professor Kataoka of Tokyo
University, who is regarded as a pioneer in the field of drug delivery.
Presently, NanoCarrier has business partnerships with Nippon Kayaku, KIRIN
For more information on NanoCarrier, please visit our website at
SOURCE Debiopharm S.A.